717 terminated. 717 Phase 1, 252 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 717 | Terminated 717 |
| Phase 2 | 252 | Terminated 252 |
Follow Digestive System Diseases: new trials by email Literature Review of Digestive System Diseases trials Research Report on Digestive System Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| 4SCAR-CD44v6 T Cell Therapy Targeting Cancer CD44v6-specific CAR gene-engineered T cells - Cancers Which Are CD44v6 Positive | Phase 1 / Phase 2 | Terminated | Shenzhen Geno-Immune Medical Institute | 100 | 2026-06-01 | 2026-11-03 |
| A First-in-Human Study of BB-TL1A-VIAL-HLE in Healthy Adults and People With Ulcerative Colitis BB-TL1A-VIAL-HLE - Ulcerative Colitis (UC) | Phase 1 | Terminated | Vial Australia Pty Ltd | 16 | 2025-06-23 | 2026-01-22 |
| A Clinical Trial of PF-08046037 Alone or With Sasanlimab in Patients With Advanced or Metastatic Malignancies PF-08046037, sasanlimab - Carcinoma, Non Small Cell Lung, Carcinoma, Pancreatic Ductal | Phase 1 | Terminated | Pfizer | 8 | 2025-05-06 | 2026-04-23 |
| Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors BL-M17D1 - Breast Cancer Stage III, HER2-positive Metastatic Breast Cancer | Phase 1 | Terminated | SystImmune Inc. | 3 | 2025-04-10 | 2026-09-22 |
| A Study to Test Different Doses of BI 765049 in People With Advanced Cancer of the Colon, Rectum, Stomach, or Pancreas BI 765049 - Colorectal Carcinoma, Gastric Carcinoma | Phase 1 | Terminated | Boehringer Ingelheim | 14 | 2025-03-28 | 2026-10-27 |
| A Phase 1/2a, Single- and Multiple-dose Escalation Study of KRRO-110 KRRO-110 - Alpha-1 Anti-trypsin Deficiency, AATD | Phase 1 / Phase 2 | Terminated | Korro Bio, Inc. | 42 | 2025-01-13 | 2026-04-17 |
| A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene. PF-07985045, Gemcitabine, Nab-paclitaxel - Carcinoma, Pancreatic Ductal, Colorectal Neoplasms | Phase 1 | Terminated | Pfizer | 30 | 2024-12-10 | 2026-05-22 |
| A Study of NP-201 Acetate Injection in Healthy Adult Volunteers and in Patients With Mild-To-Moderate Active Ulcerative Colitis NP-201 acetate injection (Part A), Placebo - Healthy Adult Volunteers, Active Ulcerative Colitis | Phase 1 | Terminated | NIBEC Co., Ltd. | 35 | 2024-11-25 | 2026-06-23 |
| A Study to Learn About PF-07921585 Alone or With Other Anti-cancer Medicines in People With Cancer PF-07921585, Sasanlimab - Non Small Cell Lung Cancer, Bladder Cancer | Phase 1 | Terminated | Pfizer | 4 | 2024-11-11 | 2026-03-23 |
| A Study to Test How Well BI 3720931 is Tolerated and Whether it Improves Lung Function in People With Cystic Fibrosis (Lenticlair™ 1) BI 3720931, Placebo, Inhaler - Cystic Fibrosis | Phase 1 / Phase 2 | Terminated | Boehringer Ingelheim | 5 | 2024-11-04 | 2026-04-15 |
| A Study of PRT7732, an Oral SMARCA2 Degrader, in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation PRT7732 - Advanced Solid Tumor, Metastatic Solid Tumor | Phase 1 | Terminated | Prelude Therapeutics Incorporated | 42 | 2024-11-04 | 2026-02-02 |
| A Phase I/IIa Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD0022 as Monotherapy and in Combination With Anti-cancer Agents in Adult Participants With Tumours Harbouring a KRASG12D Mutation AZD0022, Cetuximab - Advanced Solid Tumours, Non-Small Cell Lung Cancer (NSCLC) | Phase 1 | Terminated | AstraZeneca | 17 | 2024-10-18 | 2026-03-18 |
| First-in-Human Study of ATX-559, an Oral Inhibitor of DHX9, in Patients With Advanced or Metastatic Solid Tumors, and Molecularly Defined Cancers ATX-559 - Advanced Solid Tumors, Breast Cancer Recurrent | Phase 1 | Terminated | Accent Therapeutics | 17 | 2024-10-11 | 2026-02-24 |
| A Study to Assess the Adverse Events and How Intravenously Infused Livmoniplimab in Combination With Budigalimab Moves Through the Bodies of Adult Chinese Participants With Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) Livmoniplimab, Budigalimab - Hepatocellular Carcinoma (HCC) | Phase 1 | Terminated | AbbVie | 3 | 2024-09-11 | 2026-10-21 |
| A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the Body of People With Cancer When Taken Alone or With Other Anti-cancer Medicines. PF-07826390, sasanlimab, SOC (anti-PD-1 + platinum -based chemo) - Neoplasms, Non-small-cell Lung Cancer | Phase 1 | Terminated | Pfizer | 10 | 2024-09-06 | 2026-02-23 |
| A Study of SGN-MesoC2 in Advanced Solid Tumors PF-08052666 - Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms | Phase 1 | Terminated | Seagen, a wholly owned subsidiary of Pfizer | 19 | 2024-08-02 | 2026-07-07 |
| A Study to Evaluate CC-486/Onureg in Participants With Moderate or Severe Hepatic Impairment Compared With Normal Hepatic Function in Participants With Myeloid Malignancies Onureg - Hepatic Insufficiency, Neoplasms | Phase 1 | Terminated | Bristol-Myers Squibb | 2 | 2024-07-12 | 2026-01-12 |
| A Study of PHN-010 in Patients With Advanced Solid Tumors PHN-010 - Lung Cancer, Colon Cancer | Phase 1 | Terminated | Pheon Therapeutics | 26 | 2024-07-01 | 2026-01-29 |
| A Phase I, the Study to Evaluate the Safety, Immunogenicity and Efficacy of YS-HBV-002 YS-HBV-002 - Chronic Hepatitis B | Phase 1 | Terminated | Yisheng Biopharma (Singapore) Pte. Ltd. | 16 | 2024-07-01 | 2025-02-24 |
| A Phase 1a/1b Study of ACTM-838 in Patients With Advanced Solid Tumors ACTM-838 - Solid Tumor | Phase 1 | Terminated | Actym Therapeutics, Inc. | 10 | 2024-06-05 | 2025-10-15 |
Showing 20 of 717. Sign in to see all of them.
Colorectal Neoplasms (188) · Pancreatic Neoplasms (153) · Carcinoma, Non-Small-Cell Lung (107) · Stomach Neoplasms (87) · Carcinoma, Hepatocellular (79) · Colonic Neoplasms (64) · Melanoma (63) · Neoplasms (63) · Ovarian Neoplasms (61) · Breast Neoplasms (60) · Neoplasm Metastasis (58) · Squamous Cell Carcinoma of Head and Neck (51) · Rectal Neoplasms (49) · Esophageal Neoplasms (46) · Carcinoma, Renal Cell (44)
Neoplasms by Site (530) · Digestive System Neoplasms (524) · Neoplasms (479) · Gastrointestinal Diseases (413) · Gastrointestinal Neoplasms (322) · Intestinal Diseases (315) · Colonic Diseases (256) · Intestinal Neoplasms (252) · Neoplasms by Histologic Type (238) · Rectal Diseases (230) · Neoplasms, Glandular and Epithelial (206) · Endocrine System Diseases (205) · Endocrine Gland Neoplasms (202) · Carcinoma (179)
Gemcitabine (62) · pembrolizumab (40) · Capecitabine (32) · Fluorouracil (30) · Oxaliplatin (30) · 130-nm albumin-bound paclitaxel (28) · Bevacizumab (23) · Cetuximab (23) · Nivolumab (23) · Irinotecan (20) · Leucovorin (20) · Radiotherapy (19) · Cyclophosphamide (18) · Albumin-Bound Paclitaxel (17) · Cisplatin (16)
National Cancer Institute (NCI) (26) · Pfizer (22) · Merck Sharp & Dohme LLC (13) · Washington University School of Medicine (13) · Novartis Pharmaceuticals (12) · Incyte Corporation (11) · Bristol-Myers Squibb (10) · Hoffmann-La Roche (10) · GlaxoSmithKline (8) · M.D. Anderson Cancer Center (8) · Massachusetts General Hospital (8) · AstraZeneca (7) · Boehringer Ingelheim (7) · AbbVie (6) · Eli Lilly and Company (6)
United States (520) · Spain (59) · Australia (57) · United Kingdom (55) · France (47) · South Korea (42) · Germany (38) · Canada (36) · Belgium (34) · Taiwan (34) · China (28) · Italy (25) · Japan (25) · New Zealand (24) · Netherlands (21)
Amy Lightner, MD (5) · David S Schrump, M.D. (5) · Andrew Ko, MD (3)
PMID 31527168, PMID 35046060, PMID 39863139, PMID 18197583, PMID 18668653, PMID 18845990, PMID 19525947, PMID 19738454, PMID 20305636, PMID 20930628, PMID 21516509, PMID 22634621, PMID 23553066, PMID 24041792, PMID 24231241, PMID 24285980, PMID 24995515, PMID 25290091, PMID 25627002, PMID 25679067, PMID 27137491, PMID 27256874, PMID 27681866, PMID 27784746, PMID 28576557, PMID 28677263, PMID 28939558, PMID 29119276, PMID 29158367, PMID 29322091, PMID 29572094, PMID 29735994, PMID 29808006, PMID 29934438, PMID 30139840, PMID 30634942, PMID 30796035, PMID 30858085, PMID 30911664, PMID 31401903, PMID 31802410, PMID 32238921, PMID 32361265, PMID 32379297, PMID 32410080, PMID 32524319, PMID 32598257, PMID 32788205, PMID 32819975, PMID 32891715
2017 (12), 2023 (11), 2018 (10), 2019 (9), 2014 (7), 2015 (6), 2016 (6), 2009 (3), P30CA043703 (3), P50CA196510 (3), P30CA068485 (2), U01CA121947 (2), 2025 (1), N01CM00071 (1), N01CM00100 (1)